Investment in MSD Site Secures Site to Create Base for New Life Science Companies

Investment in MSD Site

Scotland's life sciences sector received a major boost on the 11th January with the announcement that newly-formed BioCity Scotland Limited has acquired the former-MSD research facility at Newhouse in order to develop a dedicated base in central Scotland for growing bioscience, pharmaceutical, med tech and healthcare companies.

This joint venture between BioCity Nottingham and Roslin BioCentre has been enabled by the generous gifting of the site to BioCity Scotland by MSD (operating in the US and Canada as Merck & Co).

The agreement unlocks over 130,000 sq ft of purpose-built laboratories and offices on the 23 acre site capable of supporting pre-clinical drug discovery and development by a range of independent, ambitious companies.

In addition there are administrative and conference facilities to provide support and networking capabilities for the client companies.

The rejuvenated site will complement the existing provision of space for life science firms in Scotland by catering for growing companies wanting a central base on the M8 just 15 miles from Glasgow and 33 miles from Edinburgh. In addition to over 130,000 sq ft of pharma-quality fully-fitted laboratory and office space, BioCity Scotland provides access to a wide range of state-of-the-art equipment, available to rent at very competitive rates.

On site business support will ensure that companies are able to tap into a developed support system and funding opportunities to assist their growing business needs.